Roche's Oseltamivir Efficacy Questioned by New REMAP-CAP Trial Results
A recent study by the REMAP-CAP Investigators has cast doubt on the efficacy of oseltamivir, a drug widely used for treating influenza in critically ill patients. The study, which is an international Bayesian adaptive platform trial, compared the effects of five and ten-day courses of oseltamivir against a control group receiving no antiviral treatment. The trial was halted early due to the drug's inferiority, with results showing no significant benefit in reducing mortality among critically ill patients. This finding challenges the long-standing belief in oseltamivir's effectiveness, which was largely based on observational data from the 2009 H1N1 pandemic and industry-funded studies. The trial's results indicate that oseltamivir may not provide the lifesaving benefits previously claimed, and its use in critically ill patients should be reconsidered. 
